South Korea's drug safety ministry has authorized the use of the two-dose coronavirus vaccine developed by U.S.-based biotechnology company Novavax.
The protein-based shot is the fifth to be approved for use in the country, following vaccines by AstraZeneca, Pfizer, Johnson & Johnson and Moderna.
It will be distributed by SK Bioscience, a unit of SK Group, and administered starting in the middle of February.
The ministry announced the decision Wednesday, saying Novavax's two-dose vaccine regimen will be administered 21 days apart in adults aged 18 and up.
It added the possibility of authorizing the vaccine for booster shots, pending further review.
Authorities, however, have yet to determine how effective the vaccine is against the more transmissible Omicron variant.
Please send comments to email@example.com / copyright © tbs. Unauthorized redistribution prohibited.